TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery
Brief Summary: The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.


Options:
A: Arm Label: fibrinogen concentrate-treated group; Type: EXPERIMENTAL; Interventions: Drug: fibrinogen concentrate | Arm Label: non-fibrinogen concentrate-treated group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: fibrinogen concentrate; Assigned to Arm(s): fibrinogen concentrate-treated group
B: Arm Label: Haemocomplettan® P; Type: ACTIVE_COMPARATOR; Interventions: Biological: Haemocomplettan® P | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline solution | Intervention Type: BIOLOGICAL; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: BIOLOGICAL; Name: Saline solution; Assigned to Arm(s): Saline solution
C: Arm Label: Fibrinogen Concentrate (Human); Type: EXPERIMENTAL; Interventions: Biological: Fibrinogen Concentrate (Human) (FCH) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Fibrinogen Concentrate (Human) (FCH); Assigned to Arm(s): Fibrinogen Concentrate (Human) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Freezed-dried plasma; Type: EXPERIMENTAL; Interventions: Drug: Freezed-dried plasma | Arm Label: Fresh-frozen plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh-frozen plasma | Intervention Type: DRUG; Name: Freezed-dried plasma; Assigned to Arm(s): Freezed-dried plasma | Intervention Type: DRUG; Name: Fresh-frozen plasma; Assigned to Arm(s): Fresh-frozen plasma

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery
Brief Summary: The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.


Options:
A: Arm Label: Haemocomplettan® P; Type: ACTIVE_COMPARATOR; Interventions: Biological: Haemocomplettan® P | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline solution | Intervention Type: BIOLOGICAL; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: BIOLOGICAL; Name: Saline solution; Assigned to Arm(s): Saline solution
B: Arm Label: Coagulation factor concentrates; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate | Arm Label: Fresh Frozen Plasma; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fresh Frozen Plasma blood type 0, A, B and AB | Intervention Type: DRUG; Name: Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate; Assigned to Arm(s): Coagulation factor concentrates | Intervention Type: DRUG; Name: Fresh Frozen Plasma blood type 0, A, B and AB; Assigned to Arm(s): Fresh Frozen Plasma
C: Arm Label: Fibrinogen Concentrate; Type: EXPERIMENTAL; Interventions: Drug: Fibrinogen Concentrate | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Isotonic Saline | Intervention Type: DRUG; Name: Fibrinogen Concentrate; Assigned to Arm(s): Fibrinogen Concentrate | Intervention Type: DRUG; Name: Isotonic Saline; Assigned to Arm(s): Placebo
D: Arm Label: Liberal (10 g/dL) Transfusion Strategy; Type: EXPERIMENTAL; Interventions: Biological: Liberal (10 g/dL) Transfusion Strategy | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Biological: Restrictive (Symptomatic) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Liberal (10 g/dL) Transfusion Strategy; Assigned to Arm(s): Liberal (10 g/dL) Transfusion Strategy | Intervention Type: BIOLOGICAL; Name: Restrictive (Symptomatic) Transfusion Strategy; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Haemocomplettan® P in Patients Experiencing Acute Bleeding While Undergoing Aortic Replacement Surgery
Brief Summary: The primary purpose is to show that administration of Haemocomplettan® P significantly reduces the amount of blood products needed during aortic surgery.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: Metoprolol controlled release (CR) | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Metoprolol controlled release (CR); Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): B
B: Arm Label: IG1202-A (Vascular); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-B (Hepatic); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-C (Soft Tissue); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Arm Label: IG1202-D (Spinal); Type: EXPERIMENTAL; Interventions: Biological: Human thrombin, Biological: Bovine thrombin | Intervention Type: BIOLOGICAL; Name: Human thrombin; Assigned to Arm(s): IG1202-A (Vascular), IG1202-B (Hepatic), IG1202-C (Soft Tissue), IG1202-D (Spinal) | Intervention Type: BIOLOGICAL; Name: Bovine thrombin; Assigned to Arm(s): IG1202-A (Vascular), IG1202-B (Hepatic), IG1202-C (Soft Tissue), IG1202-D (Spinal)
C: Arm Label: Tranexamic Acid; Type: EXPERIMENTAL; Interventions: Drug: tranexamic acid diluted in 100 ml of saline solution (loading dose), Drug: tranexamic acid undiluted (continous infusion) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: tranexamic acid diluted in 100 ml of saline solution (loading dose); Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: tranexamic acid undiluted (continous infusion); Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Haemocomplettan® P; Type: ACTIVE_COMPARATOR; Interventions: Biological: Haemocomplettan® P | Arm Label: Saline solution; Type: PLACEBO_COMPARATOR; Interventions: Biological: Saline solution | Intervention Type: BIOLOGICAL; Name: Haemocomplettan® P; Assigned to Arm(s): Haemocomplettan® P | Intervention Type: BIOLOGICAL; Name: Saline solution; Assigned to Arm(s): Saline solution

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms
Brief Summary: The purpose of this study was to determine whether 2 alternative dosing regimens of Fabrazyme (Agalsidase beta) (1.0 mg/kg every 4 weeks or 0.5 mg/kg every 2 weeks) were effective in treatment-naïve pediatric participants without severe symptoms. Participants were to be treated for 5 years.


Options:
A: Arm Label: Fabrazyme 0.5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Arm Label: Fabrazyme 1.0 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Agalsidase beta | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 0.5 mg/kg | Intervention Type: BIOLOGICAL; Name: Agalsidase beta; Assigned to Arm(s): Fabrazyme 1.0 mg/kg
B: Arm Label: Fabrazyme; Type: EXPERIMENTAL; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme
C: Arm Label: Agalsidase alfa (Cohort 1); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Arm Label: Agalsidase Alfa (Cohort 2); Type: EXPERIMENTAL; Interventions: Drug: Agalsidase alfa | Intervention Type: DRUG; Name: Agalsidase alfa; Assigned to Arm(s): Agalsidase Alfa (Cohort 2), Agalsidase alfa (Cohort 1)
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: Fabrazyme (agalsidase beta); Type: ACTIVE_COMPARATOR; Interventions: Biological: Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Fabrazyme (agalsidase beta); Assigned to Arm(s): Fabrazyme (agalsidase beta) | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 4 Study of Losartan in Hypertensive Men and Women With Obstructive Sleep Apnea Before and After Continuous Positive Airway Pressure (CPAP) Treatment
Brief Summary: Obstructive sleep apnea (OSA) is a highly prevalent condition in hypertensive patients. The renin-angiotension-aldosterone-system (RAAS) has a central role in blood pressure control. An angiotensin-II-antagonist, Losartan, is an effective antihypertensive drug. However, some patients respond to this drug worse than the others, and it is a clinical praxis to either increase the dosage and/or add another drug. There is limited data regarding the impact of antihypertensive drugs in OSA patients, i.e., whether or not OSA may constitute the subgroup of therapy-resistent hypertensive patients. In the literature, there is no data, either, whether or not CPAP treatment may have an additive blood pressure lowering impact in this certain subgroup.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: CPAP | Intervention Type: DEVICE; Name: CPAP; Assigned to Arm(s): 2
B: Intervention Type: PROCEDURE; Name: continuous positive airway pressure; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Losartan | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Losartan, Other: CPAP | Intervention Type: DRUG; Name: Losartan; Assigned to Arm(s): 1, 2, 3 | Intervention Type: OTHER; Name: CPAP; Assigned to Arm(s): 3
D: Intervention Type: DEVICE; Name: Continuous positive airway pressure; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation and the Natural History of HIV-Associated Emphysema
Brief Summary: People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.


Options:
A: Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
C: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation and the Natural History of HIV-Associated Emphysema
Brief Summary: People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.


Options:
A: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
B: Arm Label: Smoking counseling, Placebo; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking counseling, Drug: placebo | Arm Label: Smoking counseling, Varenicline; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking counseling, Drug: varenicline | Intervention Type: BEHAVIORAL; Name: Smoking counseling; Assigned to Arm(s): Smoking counseling, Placebo, Smoking counseling, Varenicline | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Smoking counseling, Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Smoking counseling, Placebo
C: Arm Label: Arm I (varenicline); Type: EXPERIMENTAL; Interventions: Drug: varenicline | Arm Label: Arm II (nicotine patch); Type: ACTIVE_COMPARATOR; Interventions: Drug: nicotine patch | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): Arm I (varenicline) | Intervention Type: DRUG; Name: nicotine patch; Assigned to Arm(s): Arm II (nicotine patch)
D: Arm Label: Sugar Pill; Type: PLACEBO_COMPARATOR; Interventions: Other: Sugar Pill | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Bupropion HCl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl | Intervention Type: OTHER; Name: Sugar Pill; Assigned to Arm(s): Sugar Pill | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Bupropion HCl; Assigned to Arm(s): Bupropion HCl

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation and the Natural History of HIV-Associated Emphysema
Brief Summary: People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.


Options:
A: Arm Label: Varenicline treatment as usual (TAU); Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Varenicline directly observed therapy; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline directly observed therapy, Varenicline treatment as usual (TAU)
B: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
C: Arm Label: 8 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 24 weeks transdermal nicotine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Transdermal nicotine patch | Arm Label: 52 weeks transdermal nicotine; Type: EXPERIMENTAL; Interventions: Drug: Transdermal nicotine patch | Intervention Type: DRUG; Name: Transdermal nicotine patch; Assigned to Arm(s): 24 weeks transdermal nicotine, 52 weeks transdermal nicotine, 8 weeks transdermal nicotine
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation and the Natural History of HIV-Associated Emphysema
Brief Summary: People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.


Options:
A: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: 300 mg/day bupropion-sr | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: 0 mg/day bupropion-sr | Intervention Type: DRUG; Name: 300 mg/day bupropion-sr; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: 0 mg/day bupropion-sr; Assigned to Arm(s): 2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Naltrexone, Drug: Varenicline | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: Naltrexone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): 1, 2
D: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Smoking Cessation and the Natural History of HIV-Associated Emphysema
Brief Summary: People that are infected with HIV appear to be especially susceptible to the adverse effects of cigarette smoking. The purpose of this study is to determine if quitting smoking by using a specialized smoking cessation treatment can prevent one from developing accelerated lung damage, particularly emphysema.


Options:
A: Arm Label: Healthy Control - Non-smoking; Type: OTHER; Interventions: Other: Biological Control | Arm Label: Healthy Control - Smoker; Type: OTHER; Interventions: Other: Biological Control | Arm Label: HIV Smoking Cessation Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline tartrate, Drug: Nicotine Replacement Therapy | Arm Label: Motivational Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interview | Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: DRUG; Name: Nicotine Replacement Therapy; Assigned to Arm(s): HIV Smoking Cessation Arm | Intervention Type: OTHER; Name: Biological Control; Assigned to Arm(s): Healthy Control - Non-smoking, Healthy Control - Smoker | Intervention Type: BEHAVIORAL; Name: Motivational Interview; Assigned to Arm(s): Motivational Intervention
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling and Nicotine replacement (CN) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: Counseling, Nicotine replacement and Bupropion (CNB) | Intervention Type: BEHAVIORAL; Name: Counseling and Nicotine replacement (CN); Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: Counseling, Nicotine replacement and Bupropion (CNB); Assigned to Arm(s): 3
C: Arm Label: Bupropion; Type: EXPERIMENTAL; Interventions: Drug: Bupropion, Behavioral: Smoking Cessation Counseling | Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Behavioral: Smoking Cessation Counseling | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Behavioral: Smoking Cessation Counseling | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BEHAVIORAL; Name: Smoking Cessation Counseling; Assigned to Arm(s): Bupropion, Placebo, Varenicline
D: Arm Label: P; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupropion HCl ER | Intervention Type: DRUG; Name: Bupropion HCl ER; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): P

Answer: A